- Home
- ALPS vs ADAG Comparison
ALPS vs ADAG Comparison
Compare ALPS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | ADAG |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Malaysia | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 146.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALPS | ADAG |
|---|---|---|
| Price | $1.11 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 48.2K | ★ 221.5K |
| Earning Date | 07-24-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.33 |
| 52 Week High | $1.72 | $4.58 |
Technical Indicators
Market Signals| Indicator | ALPS | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 54.64 |
| Support Level | $0.87 | $1.69 |
| Resistance Level | $1.11 | $4.58 |
| Average True Range (ATR) | 0.15 | 0.47 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 29.81 | 43.84 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.